Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.43 |
| ▸ | KIT | P10721 | 4/20 | 0.43 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.41 |
| ▸ | CLK1 | P49759 | 5/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15241762 | 0.80 | BRD4 (0.49) | BRD4NTRK1KITMAP3K11DYRK1A | |
| SCHEMBL12829259 | 0.80 | NTRK1 (0.66) | BRD4NTRK1KITMAP3K11DYRK1A | |
| SCHEMBL31228005 | 0.77 | BRD4 (0.54) | BRD4KITDYRK1ACLK1DYRK2 | |
| SCHEMBL68662 | 0.77 | DYRK1A (0.58) | BRD4NTRK1DYRK1ACLK1DYRK2 | |
| SCHEMBL1045946 | 0.77 | BRD4 (0.54) | BRD4KITDYRK1ACLK1DYRK2 | |
| SCHEMBL1053943 | 0.77 | JAK2 (0.58) | BRD4KITMAPK1CHEK1AXL | |
| SCHEMBL11968454 | 0.77 | BRD4 (0.47) | BRD4NTRK1KITMAP3K11DYRK1A | |
| SCHEMBL7912970 | 0.77 | BRD4 (0.47) | BRD4KITMAP3K11DYRK1ACLK1 | |
| SCHEMBL1880862 | 0.77 | BRD4 (0.47) | BRD4KITMAP3K11DYRK1ACLK1 | |
| SCHEMBL24005850 | 0.77 | PRMT5 (0.42) | NTRK1KITMAP3K11DYRK1ACLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | BRD4 1103/4885NTRK1 515/4885KIT 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.